167 related articles for article (PubMed ID: 24943657)
21. Striatonigral distribution of a fluorescent reporter following intracerebral delivery of genome editors.
Neuman SS; Metzger JM; Bondarenko V; Wang Y; Felton J; Levine JE; Saha K; Gong S; Emborg ME
Front Bioeng Biotechnol; 2023; 11():1237613. PubMed ID: 37564994
[No Abstract] [Full Text] [Related]
22. Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain.
Cunningham J; Pivirotto P; Bringas J; Suzuki B; Vijay S; Sanftner L; Kitamura M; Chan C; Bankiewicz KS
Mol Ther; 2008 Jul; 16(7):1267-75. PubMed ID: 18523450
[TBL] [Abstract][Full Text] [Related]
23. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
[TBL] [Abstract][Full Text] [Related]
24. T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery.
Richardson RM; Gimenez F; Salegio EA; Su X; Bringas J; Berger MS; Bankiewicz KS
Neurosurgery; 2011 Jul; 69(1):154-63; discussion 163. PubMed ID: 21430597
[TBL] [Abstract][Full Text] [Related]
25. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.
Bartus RT; Brown L; Wilson A; Kruegel B; Siffert J; Johnson EM; Kordower JH; Herzog CD
Neurobiol Dis; 2011 Oct; 44(1):38-52. PubMed ID: 21704161
[TBL] [Abstract][Full Text] [Related]
26. Insights from mathematical modeling for convection-enhanced intraputamenal delivery of GDNF.
Belova E; Shaffer CL; Trapa PE
Med Biol Eng Comput; 2017 Dec; 55(12):2069-2077. PubMed ID: 28493093
[TBL] [Abstract][Full Text] [Related]
27. Effects of striatal transplantation of cells transfected with GDNF gene without pre- and pro-regions in mouse model of Parkinson's disease.
Revishchin A; Moiseenko L; Kust N; Bazhenova N; Teslia P; Panteleev D; Kovalzon V; Pavlova G
BMC Neurosci; 2016 Jun; 17(1):34. PubMed ID: 27286696
[TBL] [Abstract][Full Text] [Related]
28. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia.
Ciesielska A; Mittermeyer G; Hadaczek P; Kells AP; Forsayeth J; Bankiewicz KS
Mol Ther; 2011 May; 19(5):922-7. PubMed ID: 21102559
[TBL] [Abstract][Full Text] [Related]
29. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
Connor B
Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):896-900. PubMed ID: 11703392
[TBL] [Abstract][Full Text] [Related]
30. Enhanced nigrostriatal neuron-specific, long-term expression by using neural-specific promoters in combination with targeted gene transfer by modified helper virus-free HSV-1 vector particles.
Cao H; Zhang GR; Wang X; Kong L; Geller AI
BMC Neurosci; 2008 Apr; 9():37. PubMed ID: 18402684
[TBL] [Abstract][Full Text] [Related]
31. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
32. Convection-enhanced delivery of AAV2 in white matter--a novel method for gene delivery to cerebral cortex.
Barua NU; Woolley M; Bienemann AS; Johnson D; Wyatt MJ; Irving C; Lewis O; Castrique E; Gill SS
J Neurosci Methods; 2013 Oct; 220(1):1-8. PubMed ID: 23988614
[TBL] [Abstract][Full Text] [Related]
33. Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector.
Georgievska B; Jakobsson J; Persson E; Ericson C; Kirik D; Lundberg C
Hum Gene Ther; 2004 Oct; 15(10):934-44. PubMed ID: 15585109
[TBL] [Abstract][Full Text] [Related]
34. Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain.
Kells AP; Forsayeth J; Bankiewicz KS
Neurobiol Dis; 2012 Nov; 48(2):228-35. PubMed ID: 22019719
[TBL] [Abstract][Full Text] [Related]
35. Gene Therapy in the Management of Parkinson's Disease: Potential of GDNF as a Promising Therapeutic Strategy.
Behl T; Kaur I; Kumar A; Mehta V; Zengin G; Arora S
Curr Gene Ther; 2020; 20(3):207-222. PubMed ID: 32811394
[TBL] [Abstract][Full Text] [Related]
36. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion.
Lieberman DM; Laske DW; Morrison PF; Bankiewicz KS; Oldfield EH
J Neurosurg; 1995 Jun; 82(6):1021-9. PubMed ID: 7539062
[TBL] [Abstract][Full Text] [Related]
37. Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors.
Su X; Kells AP; Salegio EA; Salegio EA; Richardson RM; Hadaczek P; Beyer J; Bringas J; Pivirotto P; Forsayeth J; Bankiewicz KS
Mol Ther; 2010 Aug; 18(8):1490-5. PubMed ID: 20551915
[TBL] [Abstract][Full Text] [Related]
38. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Kordower JH; Emborg ME; Bloch J; Ma SY; Chu Y; Leventhal L; McBride J; Chen EY; Palfi S; Roitberg BZ; Brown WD; Holden JE; Pyzalski R; Taylor MD; Carvey P; Ling Z; Trono D; Hantraye P; Déglon N; Aebischer P
Science; 2000 Oct; 290(5492):767-73. PubMed ID: 11052933
[TBL] [Abstract][Full Text] [Related]
39. Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates.
Yin D; Valles FE; Fiandaca MS; Bringas J; Gimenez F; Berger MS; Forsayeth J; Bankiewicz KS
Neuroimage; 2011 Jan; 54 Suppl 1():S196-203. PubMed ID: 19761848
[TBL] [Abstract][Full Text] [Related]
40. Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain.
San Sebastian W; Samaranch L; Heller G; Kells AP; Bringas J; Pivirotto P; Forsayeth J; Bankiewicz KS
Gene Ther; 2013 Dec; 20(12):1178-83. PubMed ID: 24067867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
